Co-delivery of gemcitabine and mcl-1 sirna via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer
文献类型:期刊论文
作者 | Wang, Yanbing1,2; Gao, Fenghua2; Jiang, Xingwei2; Zhao, Xiao3; Wang, Yu2; Kuai, Qiyuan2; Nie, Guangjun3; He, Min2; Pan, Yingjie2; Shi, Wei1 |
刊名 | Journal of biomedical nanotechnology |
出版日期 | 2019-05-01 |
卷号 | 15期号:5页码:966-978 |
ISSN号 | 1550-7033 |
关键词 | Nanoparticles Gemcitabine Myeloid cell leukemia 1 Rna interference Pancreatic cancer |
DOI | 10.1166/jbn.2019.2762 |
通讯作者 | Shi, wei(shiw@jlu.edu.cn) ; Ren, suping(rensp12@yahoo.com) ; Yu, qun(yuqun1970@outlook.com) |
英文摘要 | Myeloid cell leukemia 1 (mcl-1) overexpression is found in various human tumors and has emerged as a promising new target for pancreatic cancer treatment. recent research has found that most pancreatic cancers develop resistance to the current first-line chemotherapeutic drug, gemcitabine (gem), and high expression of mcl-1 can reduce the sensitivity of pancreatic cancer cells to gem chemotherapy. therefore, novel strategies, such as combination therapy, to overcome resistance of gem chemotherapy are needed urgently. here, we employed a lipid-based delivery system (lps) to co-deliver mcl-1 sirna and gem for pancreatic cancer treatment, named lp-gem-simcl-1. lp-gem-simcl-1 exhibited an increased cellular uptake, enhanced mcl-1 down-regulation efficacy, and significant cytotoxicity in the human pancreatic carcinoma cell lines panc-1 and bxpc-3. furthermore, tumor inhibition in vivo proved that lp-gem-simcl-1 has higher anti-tumor efficiency than lp-simcl-1 plus lp-gem, indicating the synergistic anti-tumor effects of gem and simcl-1. meanwhile, histological analysis demonstrated that lps could efficiently co-deliver gem and mcl-1 sirna to cancerous cells and overcome the resistance of gem. taken together, our results offer proof that lp-gem-simcl-1 is an effective co-delivery system to treat pancreatic cancers and may serve as a valuable tool for developing new strategies for cancer therapy. |
WOS关键词 | GROWTH IN-VITRO ; TARGETING MCL-1 ; INHIBITOR ; EXPRESSION ; SURVIVAL ; THERAPY |
资助项目 | National Key R&D Program of China[2017YFC1307500] ; National Science and Technology Major Project of China[2018ZX09J18111] ; National Open Research Project of China[ALJ17J002] ; Beijing Natural Science Foundation of China[7162143] |
WOS研究方向 | Science & Technology - Other Topics ; Materials Science |
WOS类目 | Nanoscience & Nanotechnology ; Materials Science, Biomaterials |
语种 | 英语 |
出版者 | AMER SCIENTIFIC PUBLISHERS |
WOS记录号 | WOS:000461761600009 |
资助机构 | National Key R&D Program of China ; National Science and Technology Major Project of China ; National Open Research Project of China ; Beijing Natural Science Foundation of China |
URI标识 | http://www.irgrid.ac.cn/handle/1471x/2160952 |
专题 | 高能物理研究所 |
通讯作者 | Shi, Wei; Ren, Suping; Yu, Qun |
作者单位 | 1.Jilin Univ, Coll Life Sci, Changchun 130012, Jilin, Peoples R China 2.Beijing Inst Transfus Med, Beijing 100850, Peoples R China 3.Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China 4.Beihang Univ, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100083, Peoples R China |
推荐引用方式 GB/T 7714 | Wang, Yanbing,Gao, Fenghua,Jiang, Xingwei,et al. Co-delivery of gemcitabine and mcl-1 sirna via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer[J]. Journal of biomedical nanotechnology,2019,15(5):966-978. |
APA | Wang, Yanbing.,Gao, Fenghua.,Jiang, Xingwei.,Zhao, Xiao.,Wang, Yu.,...&Yu, Qun.(2019).Co-delivery of gemcitabine and mcl-1 sirna via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer.Journal of biomedical nanotechnology,15(5),966-978. |
MLA | Wang, Yanbing,et al."Co-delivery of gemcitabine and mcl-1 sirna via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer".Journal of biomedical nanotechnology 15.5(2019):966-978. |
入库方式: iSwitch采集
来源:高能物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。